Repotrectinib is FDA approved for ROS1+ lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible. onclive.com/view/fda-appro…

Two research technician positions are immediately available in my lab Johns Hopkins Medicine Johns Hopkins Kimmel Cancer Center. You will be working on KRAS targeting in solid cancer. If interested, please apply here:
jobs.jhu.edu/job/Baltimore-…

jobs.jhu.edu/job/Baltimore-…

Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations Sandra Misale!!

Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.

Out today in Cancer Discovery our new work where we describe the genetic bases of acquired resistance to EGFR/KRAS G12C dual blockade in colorectal cancer. Here’s the link of the paper shorturl.at/EOPT8 and a thread👇:

Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to Noura Choudhury, MD Yonina Murciano-Goroff Neil Vasan Lab and the many contributing authors!! amazon.com/gp/aw/d/B0B9T5…

Aaaaand we're back!! 9 years really flew by since I was last here while working at #MSKCC ; now as a #HOfellow Cleveland Clinic. Especially humbled to reconnect with a close friend and AMAZING mentor Alexander Drilon MD at #ASCO22 !!

Excellent work from the Klebanoff lab on TCR development for an HLA-A*03:01 restricted public neoantigen generated in the context of a PIK3CA H1047L catalytic subunit hotspot mutation. rdcu.be/cMjvb

RETi resistance in lung, thyroid & other cancers can be complex. This paper includes insights into the serial kinetics of resistance acquisition, the potential emergence of RET wild type populations & the frequency of polyclonal resistance. Proud to be part of this team!

The first publication of larotrectinib in NTRK fusion+ lung cancers alone is out. Beyond the initial systemic & intracranial response gains, the ~35 month median PFS and the ~41 month median OS impress. Wonderful news for patients, advocates, and providers across the world.

Quick recap of today's presentation of Zeno in heavily pretreated NRG1+ solid tumors. Efficacy observed across tumor types with ORR of 42% in PDAC. Thanks to ASCO for the opportunity to present, Ignacio Garrido-Laguna for an excellent discussion, collaborators, and patients. #ASCO2021

I’m honored to be among the #ConquerCancer  Grant & Award Class of 2021 (CDA) and 2018 (YIA). Donors make these research opportunities possible. Give to the ASCO CONQUERS CANCER Fund to help fuel the next generation of researchers bit.ly/ASCOCONQUERSCA… #ASCO21

Congratulations to Noura Choudhury, MD on her Conquer Cancer, the ASCO Foundation ASCO Young Investigator Award. I'm lucky to co-mentor her with Helena Yu . She has an interesting trial combining amivantamab and lazertinib in patients with EGFR mutant NSCLC progressing in the CNS (almost open!).

RETpositive has officially launched! We are a patient-led coalition formed to advance research on RET+ cancers. Through our partnership with LUNGevity Foundation and a generous donation-matching program, we hope to fund lifesaving research. Join us at retpositive.org #RETcancer

Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients. google.com/amp/s/finance.…

MET IHC is back from the dead! We wrote it off as a biomarker, but pl see latest study from our group lead by Alexander Drilon MD & Robin Guo which found MET expression to predict TKI response in MET Ex 14-altered NSCLC. Twists & turns of the ever-evolving NSCLC biomarker story!

A call for rational type II TKI development. Seen through the lens of next-gen TRK inhibitor resistance in TRK fusion+ cancers. 🤓Highlights the utility of TKI type switching as a strategy for on-target resistance in oncogene-driven tumors. Emiliano Cocco Maurizio Scaltriti

Wonderful team effort from many people around the world. I want to take a second to especially thank our patients and families without whom we could not have accomplished this. We are in your debt. Shout out to the RET Renegades! nejm.org/doi/full/10.10…

Excited to chair a free online lung cancer OncLive.com webinar with Benjamin Levy covering the latest topics in management of #NSCLC Wednesday, October 14, 6:30pm EST featuring expert faculty: Alexander Drilon MD I.DagogoJackMD Joshua Reuss @kamarrone #LCSM

event.onclive.com/d/q7qppz

Our paper is officially out on this month's Cancer Discovery issue! Looking forward to seeing these results translated to clinic! Elizabeth McKenna Alberto Bardelli @sloan_kettering